scholarly journals Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease

2013 ◽  
Vol 58 (4) ◽  
pp. 785-791 ◽  
Author(s):  
Zoltan Derdak ◽  
Kristine A. Villegas ◽  
Ragheb Harb ◽  
Annie M. Wu ◽  
Aryanna Sousa ◽  
...  
Cell Cycle ◽  
2012 ◽  
Vol 11 (10) ◽  
pp. 1918-1928 ◽  
Author(s):  
Erin K. Daugherity ◽  
Gabriel Balmus ◽  
Ahmed Al Saei ◽  
Elizabeth S. Moore ◽  
Delbert Abi Abdallah ◽  
...  

2014 ◽  
Vol 279 (3) ◽  
pp. 380-390 ◽  
Author(s):  
Banrida Wahlang ◽  
Ming Song ◽  
Juliane I. Beier ◽  
K. Cameron Falkner ◽  
Laila Al-Eryani ◽  
...  

2009 ◽  
Vol 29 (9) ◽  
pp. 1431-1438 ◽  
Author(s):  
Maud Lemoine ◽  
Vlad Ratziu ◽  
Minji Kim ◽  
Mustapha Maachi ◽  
Dominique Wendum ◽  
...  

2020 ◽  
Vol 11 ◽  
Author(s):  
Silvana Y. Romero-Zerbo ◽  
María García-Fernández ◽  
Vanesa Espinosa-Jiménez ◽  
Macarena Pozo-Morales ◽  
Alejandro Escamilla-Sánchez ◽  
...  

Author(s):  
R. Mark Beattie ◽  
Anil Dhawan ◽  
John W.L. Puntis

Demographics 406Pathophysiology 406Differential diagnoses 407Presenting features 407Investigation 408Management 409Fatty liver disease is now increasingly recognized in children, particularly in the setting of obesity.The term non-alcoholic steatohepatitis (NASH) was first coined in 1980 by Ludwig to describe a pattern of liver injury in adults in which the liver histology was consistent with alcoholic hepatitis, but in whom significant alcohol consumption was denied. NASH can be considered as part of a broader spectrum of non-alcoholic fatty liver disease that extends from simple steatosis through steatohepatitis that is characterized by the potential to progress to fibrosis, cirrhosis and subsequent end stage liver disease....


Sign in / Sign up

Export Citation Format

Share Document